Please ensure Javascript is enabled for purposes of website accessibility

bluebird bio Inc. Takes Flight

By Brian Orelli, PhD – Feb 1, 2016 at 11:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Up 10.6% on no news. Welcome to biotech investing.

What: bluebird bio (BLUE 2.80%) ended up 10.6% on Monday in a surge that didn't seem to have any news behind it.

So what: Double digit moves usually don't happen by accident, but keep in mind that bluebird bio was at this level as recently as last Wednesday. Like most biotechs of late, bluebird bio's volatility has been off the charts. It seems like investors fall in and out of love with the sector on a daily basis.

BLUE Chart

BLUE data by YCharts

There were a couple of Form 13Fs filed that showed funds had purchased shares of bluebird bio. But investors shouldn't be buying because funds purchased shares sometime during the last quarter.

The fact that bluebird bio has rebounded could mean that it's reaching a floor. The company ended the September with over $700 million in cash and short term investments, so at a market cap of $1.7 billion, investors are only assigning a $1 billion value to the pipeline.

Now what: Unfortunately, bluebird bio has limited upcoming catalysts to get the company trading on fundamentals rather than sentiment about the industry. The next data update for bluebird bio's LentiGlobin gene therapy treatment for beta-thalassemia and sickle cell disease isn't expected until the American Society of Hematology meeting in early December. We will get an update in April on bluebird bio's treatment for childhood cerebral adrenoleukodystrophy using a related gene therapy called Lenti-D, but the LentiGlobin treatment has a bigger potential market and is rightfully what investors are most focused on.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bluebird Bio Stock Quote
Bluebird Bio
$6.98 (2.80%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.